# MannKind (MNKD) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/MNKD
## Company Profile
- Ticker: MNKD
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Cardio-Metabolic
## Stock Data
- Close: 3.85 USD
- Market cap: 1059699069.38 USD
- Last updated: 2026-08-12
## Business Overview
### Inhaled Drug Delivery
MannKind develops and commercializes drug-device combinations using Technosphere particles and dry-powder inhalers for rapid, deep-lung delivery.
### Commercial Portfolio
Afrezza is an inhaled mealtime insulin, Tyvaso DPI is manufactured for United Therapeutics, and FUROSCIX provides subcutaneous furosemide for fluid overload outside traditional infusion settings.
### MNKD-201
MNKD-201 is an inhaled dry-powder formulation of nintedanib being advanced for idiopathic pulmonary fibrosis through the INFLO clinical program.
### Ralinepag DPI
MNKD-1501 is an inhaled ralinepag program being developed with United Therapeutics for pulmonary hypertension.
### Orphan-Lung Pipeline
MannKind is applying its pulmonary-delivery expertise to additional orphan lung diseases, including conditions that currently require prolonged multidrug treatment.
## Why The Stock Is Moving

As of Aug 12, 2026, MNKD closed up 0.26% at $3.85. No new same-company headline was identified in the current news window.

## Future Catalysts

- First patient enrollment in the Phase 2 INFLO-2 study of MNKD-201 in the second quarter of 2026.
- FDA action on the pediatric Afrezza indication by May 29, 2026.
- FDA action on the FUROSCIX ReadyFlow autoinjector by July 26, 2026.
- Topline Phase 1b INFLO-1 data for MNKD-201 in the third quarter of 2026.

## Recent News
- 2026-08-05 20:01 EST — [MannKind Reports Second Quarter 2026 Financial Results and Provides Business Update](https://biopharmsignal.com/news/MNKD/mannkind-reports-second-quarter-2026-financial-results-and-provides-business-upd-f2b608a1) — Source: MannKind
- 2026-07-29 10:30 EST — [MannKind Reports Positive Phase 1b INFLO-1 Results, Demonstrating Safety and Tolerability of Nintedanib DPI and Clinical Validation of Its DPI Technology in IPF](https://biopharmsignal.com/news/MNKD/mannkind-reports-positive-phase-1b-inflo-1-results-demonstrating-safety-and-tole-a3fa2397) — Source: MannKind
- 2026-07-28 20:01 EST — [MannKind to Report Second Quarter Financial Results and Host Conference Call on August 5, 2026](https://biopharmsignal.com/news/MNKD/mannkind-to-report-second-quarter-financial-results-and-host-conference-call-on--73ad1212) — Source: MannKind
- 2026-07-24 10:35 EST — [MannKind Announces $50 Million Private Placement](https://biopharmsignal.com/news/MNKD/mannkind-announces-50-million-private-placement-acb8f8d7) — Source: MannKind
- 2026-07-24 10:30 EST — [MannKind Announces FDA Approval of Furoscix ReadyFlow™, the First and Only Autoinjector Delivering IV-Equivalent Diuretic Therapy for the Treatment of Edema in Adults with Heart Failure or Chronic Kidney Disease](https://biopharmsignal.com/news/MNKD/mannkind-announces-fda-approval-of-furoscix-readyflow-the-first-and-only-autoinj-fc4f89fc) — Source: MannKind